Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Tianjiao Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-4719-6071; OpenAlex author ID A5100736718. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2019: 3 papers · 2020: 4 papers · 2021: 3 papers · 2022: 3 papers · 2023: 3 papers · 2024: 1 paper

Papers 17

  1. The GFPT2-O-GlcNAcylation-YBX1 axis promotes IL-18 secretion to regulate the tumor immune microenvironment in pancreatic cancer. First author DOI 10.1038/s41419-024-06589-7↗
  2. Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1002/ijc.34468↗
  3. Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2023.216411↗
  4. Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/febs.16879↗
  5. Neoadjuvant chemotherapy endows CD9 with prognostic value that differs between tumor and stromal areas in patients with pancreatic cancer. Co-author DOI 10.1002/jcla.24517↗
  6. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.01.026↗
  7. Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.104016↗
  8. Human splenic TER cells: A relevant prognostic factor acting via the artemin-GFRα3-ERK pathway in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33410↗
  9. Activation of the PX1/IL-1β axis in CD41+/CD62P+ platelets enhances pancreatic ductal adenocarcinoma invasion and metastasis Co-author DOI 10.21203/rs.3.rs-307202/v1↗
  10. Upregulation of KLK8 Predicts Poor Prognosis in Pancreatic Cancer. First author DOI 10.3389/fonc.2021.624837↗
  11. Killing the "BAD": Challenges for immunotherapy in pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2020.188384↗
  12. Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective. Co-author DOI 10.1016/j.csbj.2020.11.018↗
  13. TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway. Co-author DOI 10.1038/s41388-020-01407-8↗
  14. Precise and efficient silencing of mutant Kras G12D by CRISPR-CasRx controls pancreatic cancer progression. Co-author DOI 10.7150/thno.46642↗
  15. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. Co-author DOI 10.1002/cam4.1957↗
  16. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.2430↗
  17. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.2147/cmar.s197911↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 16 shared papers, 2019–2024 · strength 2.10
  2. Long‐Yun Ye · 8 shared papers, 2020–2024 · strength 1.21
  3. Huaxiang Xu · 10 shared papers, 2019–2022 · strength 1.07
  4. Wenquan Wang · 9 shared papers, 2019–2022 · strength 1.00
  5. Weiding Wu · 6 shared papers, 2022–2024 · strength 1.00
  6. Kaizhou Jin · 6 shared papers, 2022–2024 · strength 1.00
  7. Wuhu Zhang · 9 shared papers, 2019–2022 · strength 0.95
  8. Heli Gao · 8 shared papers, 2019–2022 · strength 0.83
  9. Zhenyu Liao · 5 shared papers, 2022–2023 · strength 0.75
  10. Liang Liu · 7 shared papers, 2019–2022 · strength 0.72
  11. Huiru Zhang · 4 shared papers, 2022–2024 · strength 0.70
  12. Liang Liu · 5 shared papers, 2020–2022 · strength 0.63
  13. Saimeng Shi · 4 shared papers, 2022–2023 · strength 0.62
  14. Qinglin Fei · 4 shared papers, 2022–2023 · strength 0.62
  15. Shuo Li · 6 shared papers, 2019–2021 · strength 0.56
  16. Chuntao Wu · 6 shared papers, 2019–2021 · strength 0.56
  17. Xuan Lin · 4 shared papers, 2020–2023 · strength 0.52
  18. Xuan Han · 4 shared papers, 2020–2022 · strength 0.45
  19. Wang Jiang · 3 shared papers, 2020–2021 · strength 0.33
  20. Hao Li · 3 shared papers, 2019–2021 · strength 0.30
  21. Shirong Zhang · 3 shared papers, 2019–2021 · strength 0.28
  22. Zhiwen Xiao · 2 shared papers, 2022 · strength 0.26
  23. Hao Li · 2 shared papers, 2021–2022 · strength 0.24
  24. Chen Liu · 1 shared paper, 2024 · strength 0.24
  25. Quanxing Ni · 2 shared papers, 2019 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.